| Editor's Note: Fierce Biotech will be on a publishing break on Thursday in recognition of the Juneteenth federal holiday. We'll be back in your inbox on Friday. |
|
Download our latest fact sheet to see how Catalent’s cell line development platform delivers unmatched efficiency, stability, and yield. Download Now. 
|
|
Today’s Big NewsJun 18, 2025 |
|
In a capital-constrained environment, equipment financing offers a smart and flexible path forward. NFS Capital is here to help you keep innovating without waiting for your next funding round. Request more information. .png)
|
|
| By Gabrielle Masson The Department of Health and Human Services is allegedly canceling clinical trial funding for biotechs with ties to certain foreign investors, Fierce Biotech has learned. |
|
|
|
By Gabrielle Masson “I'm proud to report that we're on track to meet all the PDUFA targets, and that morale is good and improving at the agency,” FDA's Marty Makary said at this year’s BIO, an international convention that has attracted 23,000 attendees. |
By Fraiser Kansteiner Following a disappointing performance from the company’s CAR-T candidate in an early-stage cancer trial, BioNTech is winding down cell therapy manufacturing at its inaugural U.S. plant in Gaithersburg, Maryland. In turn, the German company is laying off 63 technical operations staffers at the site. |
Sponsored by Thermo Fisher Scientific Austin Read of Thermo Fisher Scientific discusses how combining biospecimens with real-world data is advancing diagnostics, treatment and the future of patient care. |
|
Septemeber 8-11, 2025 | Philadelphia, PA Join the industry's top minds at Fierce Pharma Week—where innovation, strategy, and partnerships converge. Don’t miss your chance to lead the future of pharma. Register Today. 
|
|
By James Waldron Scholar Rock’s investigational spinal muscular atrophy drug helped patients taking Eli Lilly’s obesity blockbuster Zepbound maintain muscle mass, offering another avenue to reach a key goal for the obesity market. |
By Kevin Dunleavy “This is probably one of the toughest years to predict,” Arda Ural, Ph.D., EY Americas Life Sciences Sector Leader, said on a conference call last week. |
By Darren Incorvaia A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in major depressive disorder. Draig Therapeutics has emerged from a partnership between Cardiff University’s Medicine Discovery Institute and SV Health Investors to tackle unmet needs in neuropsychiatry. |
By Nick Paul Taylor PwC analysts have warned the speedy evolution of the Chinese biotech sector is creating “heightened risks related to IP security, regulatory compliance and strategic alignment.” |
By Gabrielle Masson,Darren Incorvaia,James Waldron The Fierce Biotech Fundraising Tracker records venture capital rounds of $50 million or more secured by biotechs. |
By Angus Liu The value of priority review vouchers (PRVs) appears to be on the rise as concerns mount over declining supplies following the sunset of the rare pediatric disease PRV program. |
By Fraiser Kansteiner Following HHS secretary Robert F. Kennedy Jr.’s decision last week to purge the CDC’s Advisory Committee on Immunization Practices and appoint his own replacements, the 17 ousted experts are hitting back at the arguments behind the cull. |
By Darren Incorvaia A pair of professional organizations in the U.K. is calling for the biopharma industry and national government to take action to improve diversity in clinical trials. The call comes after the Association of the British Pharmaceutical Industry and the Association of Medical Research Charities held an event with industry stakeholders to identify barriers to increasing diversity in clinical research. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we unpack Fierce Medtech's Fierce 15 and spotlight startups reimagining healthcare. |
|
|---|
|
|
|
A pipeline-supporting marketing plan that includes proven tools, well-executed tactics, and a clear strategy are key to keeping your pipeline full of qualified leads. Access this valuable resource to discover how your marketing team can support your business development team in three essential areas: audience, storytelling, and performance. Download today! 
|
|
Executive Summary Biotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
Whitepaper We analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
